Recruiting × Magnetic Resonance Spectroscopy × Gastrointestinal × Clear all Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
Phase 1/2 Recruiting
92 enrolled
National Cancer Institute "Cancer Moonshot Biobank"
Recruiting
1,600 enrolled
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Phase 1 Recruiting
51 enrolled
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
Phase 2 Recruiting
40 enrolled
Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
Phase 1 Recruiting
18 enrolled
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
Phase 1 Recruiting
24 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
Phase 1 Recruiting
30 enrolled
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Phase 1 Recruiting
30 enrolled
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
Phase 1 Recruiting
24 enrolled
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Phase 2/3 Recruiting
224 enrolled
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
Phase 1 Recruiting
15 enrolled
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
Phase 1 Recruiting
48 enrolled
PNeoVCA
Phase 1/2 Recruiting
132 enrolled
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Phase 1 Recruiting
24 enrolled
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
Phase 3 Recruiting
364 enrolled
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Phase 3 Recruiting
382 enrolled
Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Treatment of Gastric Cancer With Limited Peritoneal Metastasis, ROBO-CHIP Study
Phase 2 Recruiting
40 enrolled
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Phase 1/2 Recruiting
85 enrolled
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Phase 2 Recruiting
40 enrolled
PET/CT Imaging to Evaluate Cardiac Radiation Damage in Patients With Lung or Esophageal Cancer, EUCLID Trial
Phase NA Recruiting
20 enrolled
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1/2 Recruiting
35 enrolled
AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease
Phase 1 Recruiting
36 enrolled
LAP100
Phase 3 Recruiting
356 enrolled
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Phase 2 Recruiting
25 enrolled
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Phase 3 Recruiting
300 enrolled
LOTUS
Recruiting
800 enrolled
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
Phase 2 Recruiting
43 enrolled
Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis
Phase 1 Recruiting
15 enrolled
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Phase 4 Recruiting
6 enrolled
Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer
Recruiting
70 enrolled
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
Phase 1 Recruiting
16 enrolled
Investigational Scan (68Ga-FAPI-46 PET/CT) for Imaging of Cancer-Associated Fibroblasts for Localized Pancreatic Ductal Adenocarcinoma
Phase 2 Recruiting
130 enrolled
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Phase 1 Recruiting
10 enrolled
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Phase 1 Recruiting
30 enrolled
Clinical Performance of Medical Device Software "Lipidica 1.0" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening
Phase NA Recruiting
419 enrolled
Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer
Phase 2 Recruiting
36 enrolled
Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial
Phase 1 Recruiting
36 enrolled
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
Phase 2 Recruiting
26 enrolled
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
Phase 1 Recruiting
24 enrolled
Pilot Study of Pancreatic Cancer Screening
Recruiting
250 enrolled
Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer
Phase 1 Recruiting
19 enrolled
ERASE
Phase NA Recruiting
84 enrolled
MAESTRO
Phase NA Recruiting
70 enrolled
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Phase 2 Recruiting
94 enrolled